The initiation and continuation of immune-based therapies to treat and prevent complications of inflammatory neuro-ophthalmologic disorders during the 2019 novel coronavirus (COVID-19) pandemic is the subject of considerable debate. In each case, a treatment decision must be reached based on best clinical practices for the disorder, patient comorbidities, the current state of knowledge about the pathogenesis and infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the utilization of hospital and community resources. Unfortunately, the evidence needed to standardize the decision-making process for each neuro-ophthalmologic disorder is currently absent and is likely to require months or years to develop based on the accrual of robust international data sets. In this article, we review the current understanding of SARS-CoV-2 and COVID-19 complications to provide a framework for approaching the treatment of inflammatory neuro-ophthalmic disorders during the COVID-19 viral pandemic.

在2019年新型冠状病毒（COVID-19）大流行期间，基于免疫的疗法的启动和持续治疗和预防炎症性神经眼科疾病的并发症是引起广泛争议的主题。在每种情况下，都必须根据疾病的最佳临床实践，患者合并症，关于重症急性呼吸综合征冠状病毒2（SARS-CoV-2）的发病机理和传染性的当前知识水平以及使用情况，得出治疗决定。医院和社区资源。不幸的是，目前尚缺乏标准化每种神经眼科疾病的决策过程所需的证据，并且基于可靠的国际数据集的积累，可能需要数月或数年的时间才能开发出来。在这篇文章中，